tbuckley/cabot-search huggingface dataset:
Bifactor Analysis to Disentangle the Depression-Dementia Association
Authors: Marij Zuidersma, Richard C. Oude Voshaar
Journal: JAMA Psychiatry (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
Appropriate Perspective and Context for Newly Approved Medications, Including Flibanserin—Reply
Authors: Ellen T. Laan, Loes Jaspers, Peter Leusink
Journal: JAMA Internal Medicine (2016)

In Reply We agree with Goldstein et al that it is a clinician’s task to diligently and routinely help patients to evaluate benefits, risks, and appropriateness of therapeutic options. When available, meta-analyses, not clinical opinion, should be the basis of such a risk and benefit analysis.
Safety and efficacy on TAS-102 monotherapy in clinical practice in patients with metastatic colorectal cancer (mCRC)
Authors: Daisuke Kotani, Kohei Shitara, Shota Fukuoka, Hideaki Bando, Wataru Okamoto, Takashi Kojima, Toshihiko Doi, Takayuki Yoshino
Journal: Annals of Oncology (2015)
Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials
Authors: W. Rungapiromnan, Z.Z.N. Yiu, R.B. Warren, C.E.M. Griffiths, D.M. Ashcroft
Journal: British Journal of Dermatology (2016)

Concerns have been raised regarding an increased risk of major adverse cardiovascular events (MACEs) (myocardial infarction, cerebrovascular accident or cardiovascular death) in patients treated with anti-interleukin (IL)-12/23 agents for moderate-to-severe psoriasis. We aimed to examine the risk of MACEs in adult patients with plaque psoriasis that are exposed to biologic therapies via a meta-analysis of randomized controlled trials (RCTs). Data were obtained from systematic searches in the Cochrane Library, MEDLINE and Embase, U.S. Food and Drug Administration, European Medicines Agency, individual pharmaceutical companies online search platforms and five trials registers (up to 31 March 2016). We selected RCTs reporting adverse events in adults with plaque psoriasis receiving at least one licensed dose of biologic therapy, conventional systematic therapy or placebo. We calculated Peto odds ratios (ORs) with 95% confidence intervals (CIs) and calculated I2 statistics to assess heterogeneity. Overall, 38 RCTs involving 18 024 patients were included. No MACEs were observed in 29 studies, while nine RCTs reported 10 patients experiencing MACEs. There was no statistically significant difference in risk of MACEs associated with the use of biologic therapies overall (OR 1·45, 95% CI 0·34-6·24); tumour necrosis factor-α inhibitors (adalimumab, etanercept and infliximab) (OR 0·67, 95% CI 0·10-4·63); anti-IL-17A agents (secukinumab and ixekizumab) (OR 1·00, 95% CI 0·09-11·09) or ustekinumab (OR 4·48, 95% CI 0·24-84·77). No heterogeneity was observed in these comparisons. In conclusion, the limited existing evidence suggests that licensed biologic therapies are not associated with MACEs during the short randomized controlled periods in clinical trials.
Analysis of the cost-effectiveness of zoledronic acid for the prevention of skeletal-related events in patients with prostate cancer and bone metastases: A comparison across four European countries.
Authors: M. Botteman, F. Logman, S. Kaura
Journal: Journal of Clinical Oncology (2010)

4679 Background: Zoledronic acid (ZOL) is the only bisphosphonate indicated for the prevention of skeletal related events (SREs) in patients with bone metastases secondary to prostate cancer. This analysis estimates and compares the cost-effectiveness of ZOL versus placebo (PBO) for this indication across 4 countries: France (FR), Germany (DE), Portugal (PT), and the Netherlands (NL). Methods: The incremental costs and quality-adjusted life years (QALY) associated with ZOL therapy versus PBO were estimated using a literature-based decision analytic model based on data from a randomized trial (4 mg ZOL [n = 214] versus PBO [n = 208] for 15 months). The model included assumptions about SREs, mortality, drug and administration costs, SRE costs, reduced quality of life because of SREs and bone pain, and therapy duration. The costs of SREs were estimated using primarily Diagnosis Related Group (DRG) tariff information (supplemented with published literature) in FR and DE, and using published data reporting retrospective medical record review cost analysis in NL and PT. Results: Over 15 months, the cumulative number of SREs projected was 0.83 for ZOL patients versus 1.66 for PBO patients. ZOL reduced SRE costs by €2,659 to €4,005, depending on the country. The greatest SRE costs savings were estimated to occur in NL, followed by PT, DE, and FR. Including drug costs, ZOL reduced total costs by €62 in PT and €301 in NL, but increased costs by €562 in DE and €1,022 in FR vs. PBO. However, ZOL also increased quality-adjusted survival by 0.03566 QALY per patient, resulting in an incremental cost per QALY gained versus PBO of €15,770 in DE and €28,648 in FR. In all countries the cost-effectiveness ratio with ZOL treatment was favorable and substantially below the internationally accepted €50,000/QALY threshold value. Costs and QALYs were saved with ZOL in PT and NL. Conclusions: In patients with bone metastasis secondary to prostate cancer, ZOL is shown to be economically attractive. The cost-effectiveness ratio for ZOL is below standard cost-effectiveness thresholds observed by most healthcare systems. In PT and NL, ZOL is also cost saving versus PBO. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Novartis Novartis Novartis Novartis
A phase I study of DNIB0600A, an antibody-drug conjugate (ADC) targeting NaPi2b, in patients (pts) with non-small cell lung cancer (NSCLC) or platinum-resistant ovarian cancer (OC).
Authors: Howard A. Burris, Michael S. Gordon, David E. Gerber, David R. Spigel, David S. Mendelson, Joan H. Schiller, Yulei Wang, Younjeong Choi, Robert S. Kahn, Katie Wood, Daniel J. Maslyar, Jeffrey R. Infante
Journal: Journal of Clinical Oncology (2014)

2504 Background: NaPi2b (SLC34A2) is a multi-transmembrane, sodium-dependent phosphate transporter expressed in ~70% non-squamous NSCLC and ~90% OC. DNIB0600A is an ADC consisting of a humanized IgG1 anti-NaPi2b monoclonal antibody conjugated to an anti-mitotic agent MMAE that shows anti-proliferative activity in xenograft models . Methods: This study evaluated safety and activity of DNIB0600A (0.2-2.8 mg/kg) given by intravenous infusion every 3 weeks (q3w) to pts with NSCLC or platinum-resistant OC. A traditional 3+3 design was used for dose escalation followed by expansion at the recommended Phase 2 dose (RP2D) of 2.4 mg/kg in patients with NSCLC and OC. Tumor NaPi2b expression was evaluated by immunohistochemistry (IHC) in archival tissue. Results: As of 10 Dec 2013, 73 pts have enrolled (43 NSCLC; 30 OC), median age 62 (range 39-85), PS 0-1, median number of prior regimens 3 (1-10) in NSCLC, and 5 (1-12) in OC. Pts received a median of 4 (range 1-28) cycles of DNIB0600A. One pt experienced a DLT (Grade 3 dyspnea) at 1.8 mg/kg; no additional DLTs occurred through the maximally administered dose of 2.8 mg/kg. The most common related AEs (all grades) were fatigue (55%), nausea (40%), peripheral neuropathy (36%), decreased appetite (34%), vomiting (26%), and alopecia (19%). Related Grade 3/4 adverse events included neutropenia (8%), anemia, peripheral neuropathy, and pneumonia (each 3%), dehydration, dyspnea, fatigue, hyperglycemia, hyperkalemia, hypertensions, transaminitis, and URI (each 1%)— only dyspnea led to study treatment discontinuation. At the RP2D of 2.4 mg/kg q3w, 7/17 (41%) of IHC 2/3+ pts with OC had confirmed PRs (DoR range 1.4+ to 9.4+ months). In NSCLC, 2/21 (10%) of IHC 2/3+ pts had confirmed PRs (DoR 4.3 and 4.8 months), and 5/21 (24%) had unconfirmed PRs for best response. No pt with an IHC Score of 0 showed clinical response by RECIST criteria. + : censored. Conclusions: DNIB0600A administered q3w has an encouraging safety profile and evidence of anti-tumor activity in both OC and NSCLC. These data support Phase 2 development in OC with further clinical evaluation of DNIB0600A in NSCLC. Clinical trial information: NCT01375842.
A Simple PSA-Based Computational Approach Predicts the Timing of Cancer Relapse in Prostatectomized Patients
Authors: Ilaria Stura, Domenico Gabriele, Caterina Guiot
Journal: Cancer Research (2016)

Abstract Recurrences of prostate cancer affect approximately one quarter of patients who have undergone radical prostatectomy. Reliable factors to predict time to relapse in specific individuals are lacking. Here, we present a mathematical model that evaluates a biologically sensible parameter (α) that can be estimated by the available follow-up data, in particular by the PSA series. This parameter is robust and highly predictive for the time to relapse, also after administration of adjuvant androgen deprivation therapies. We present a practical computational method based on the collection of only four postsurgical PSA values. This study offers a simple tool to predict prostate cancer relapse. Cancer Res; 76(17); 4941–7. ©2016 AACR.
Constitutive Activation of AKT Contributes to the Pathogenesis and Survival of Blastoid Variants of Mantle Cell Lymphoma.
Authors: Martina Rudelius, Stefania Pittaluga, Trinh H.-T. Pham, Thomas Fountaine, Leticia Quintanilla-Martinez, Falko Fend, Elaine S. Jaffe, Mark Raffeld
Journal: Blood (2005)
Abstract 326: Postural Orthostatic Tachycardia Syndrome and its Associated Chronic Pain Symptoms
Authors: Chandralekha Ashangari, Amer Suleman
Journal: Circulation Research (2015)

Background and Purpose: The Postural Orthostatic Tachycardia Syndrome (POTS) affects primarily young women. POTS is a form of dysautonomia that is estimated to impact between 1,000,000 and 3,000,000 Americans, and millions more around the world. The symptoms of POTS are widespread because the autonomic nervous system plays an extensive role in regulating functions throughout the body. The aim of this study is to determine the chronic pain symptoms in Postural Orthostatic tachycardia syndrome (POTS) patients. Method: Two hundred fifty-five (255) POTS patients were randomly selected from our clinic (January 2014 to March 2015) , reviewed the medical records of 255 POTS patients for chronic pain symptoms and performed data analysis. Results: Two hundred thirty-three of the 255 (91%) patients are females (n=233, age 29.20 ± 10.32), Twenty-three of the 255 (9%) patients are males (n=23, age 29.70 ± 14.52).63% (161 of the 255) had Joint Pain/aches, 51% (131 of the 255) had Chronic headache, 40% (102 of the 255) had chest pain, 31% (80 of the 255) had Migraine, 30% (76 of the 255) had Chronic back pain,16% (42 of the 255) had Heartburn,8%(20 of the 255) had Chronic pleurisy, Rheumatoid arthritis, Muscle aches, Chronic regional pain syndrome and Hip aches. Conclusion: Our study is the first to characterize that Patients with postural orthostatic tachycardia syndrome (POTS) have a very high prevalence of chronic pain symptoms.
The Clinical Relevance Of Genetics In Predicting Outcome After a First Relapse In Children With B-Cell Precursor Acute Lymphoblastic Leukaemia
Authors: Anthony V. Moorman, Amy Erhorn, Catriona Parker, Rosemary Sutton, Claire Schwab, Nicola C Venn, Peter M. Hoogerbrugge, Tamas Revesz, Vaskar Saha, Christine J Harrison
Journal: Blood (2013)
Differentiating Burkitt Lymphoma from Burkitt-like Lymphoma in Pediatrics: Report from the Japanese Pediatric Leukemia/Lymphoma Study Group B-NHL03 Study
Authors: Tomoo Osumi, Masahiro Sekimizu, Tetsuya Mori, Reiji Fukano, Yuhki Koga, Jun-ichi Ueyama, Fumiko Tanaka, Kentaro Ohki, Tetsuo Mitsui, Takeshi Mori, Shosuke Sunami, Akiko Kada, Akiko Moriya Saito, Keizo Horibe, Katsuyoshi Koh, Yoshihiro Komada, Yoshiyuki Kosaka, Koichi Ohshima, Atsuko Nakazawa, Masahito Tsurusawa, Ryoji Kobayashi, Souichi Adachi
Journal: Blood (2014)
Hearing Loss in Infants with Microcephaly and Evidence of Congenital Zika Virus Infection — Brazil, November 2015–May 2016
Authors: Mariana C. Leal, Lilian F. Muniz, Tamires S.A. Ferreira, Cristiane M. Santos, Luciana C. Almeida, Vanessa Van Der Linden, Regina C.F. Ramos, Laura C. Rodrigues, Silvio S. Caldas Neto
Journal: MMWR Morbidity and Mortality Weekly Report (2016)

Congenital infection with Zika virus causes microcephaly and other brain abnormalities (1). Hearing loss associated with other congenital viral infections is well described; however, little is known about hearing loss in infants with congenital Zika virus infection. A retrospective assessment of a series of 70 infants aged 0-10 months with microcephaly and laboratory evidence of Zika virus infection was conducted by the Hospital Agamenon Magalhaes in Brazil and partners. The infants were enrolled during November 2015-May 2016 and had screening and diagnostic hearing tests. Five (7%) infants had sensorineural hearing loss, all of whom had severe microcephaly; however, one child was tested after receiving treatment with an ototoxic antibiotic. If this child is excluded, the prevalence of sensorineural hearing loss was 5.8% (four of 69), which is similar to that seen in association with other congenital viral infections. Additional information is needed to understand the prevalence and spectrum of hearing loss in children with congenital Zika virus infection; all infants born to women with evidence of Zika virus infection during pregnancy should have their hearing tested, including infants who appear normal at birth.
Authors’ reply to Joshi
Authors: Nina Jullum Kise, May Arna Risberg, Lars Engebretsen, Ewa M Roos
Journal: BMJ (2016)

We thank Joshi for his interest in our research article.1 2

We agree that the finding of a degenerative meniscal tear on magnetic resonance imaging (MRI) is no cause for treatment, surgical or non-surgical, and that the common use of MRI in middle aged and elderly patients with chronic knee pain is costly and unwarranted. The increasing accessibility to MRI is indeed a likely contributor to the current high rate of arthroscopic knee surgery in middle aged and elderly people because a tear once shown demands to be treated even without a proven cause of symptoms.

Asymptomatic meniscal tears …
Mutaome Profiling and Retrospective Mutaome Profiling Using Archived Bone Marrow Smear In AML
Authors: Hongxing Liu, Fang Wang, Wen Teng, Yuehui Lin, Junfang Yang, Xian Zhang, Qing Yin, Xue Chen, Ping Zhu, Chunrong Tong
Journal: Blood (2013)
Feasibility of bevacizumab (BEV) plus chemotherapy in heavily pretreated ovarian cancer (OC) patients (pts): A retrospective study.
Authors: I. Asmane, J. P. Guastalla, P. Meeus, I. Moullet, P. Ardisson, L. Vincent, D. Coeffic, A. Dufresne, A. Bajard, I. L. Ray-Coquard
Journal: Journal of Clinical Oncology (2010)

e15509 Background: There is some evidence that BEV, an anti-VEGF monoclonal antibody, is active on OC. The goal of this study was to assess the combination of BEV and chemotherapy in heavily pretreated OC patients (pts) with regard to efficacy and toxicity. Methods: In this retrospective multicentric analysis, heavily pretreated OC pts receiving BEV with chemotherapy were assessed for efficacy with CA125 measurement and CT-scans. Toxicity was assessed according to NCI-CTC V3.0. Results: 43 pts from six oncologic centers were identified and included. The median number of prior chemotherapy regimen was 3 (range 1-13). BEV was combined with paclitaxel in 30 pts (69.7%), docetaxel in 9 (20.9%), and other agents in 4 (9.3%). The median number of treatment cycles was 6 (range 1-29). No toxic death was reported. Grade 3-4 toxic events occurred in 13 (30.2%) pts, including proteinuria, elevated blood pressure, hemorrhage, pelvic abscess and psychiatric disorders. Gastrointestinal perforations (GIP) and fistulas occurred in 3 (7.0%) and 6 (13.9%) pts, respectively. GIP occurred in 7% versus 0% of pts who received 4-7 and 2 prior regimens, respectively. Only 1 (2.3%) patient had venous thrombo-embolic event, whereas no arterial embolic complication was reported. The clinical benefit defined as complete (CR) and partial (PR) responses plus stable disease ≥ 3 months was 65%. The objective response rate was 40%, including 6 (15%) CR and 10 (25%) PR. Median time to progression was 3.8 months (range 0.2 -14.4 months). At last follow-up (Dec. 09), 13 pts (30.2%) were still on BEV treatment, and 31 (72%) were alive. Conclusions: The combination of chemotherapy and BEV in routine practice is feasible and active in heavily pretreated OC pts. Toxicity is manageable, but GIP and fistulas are of concern. Further studies are warranted to assess BEV plus taxanes in advanced OC. No significant financial relationships to disclose.
Bioprosthetic Valves for Transcatheter Aortic Valve Replacement
Authors: Marco Barbanti, Davide Capodanno, Corrado Tamburino
Journal: JAMA (2014)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Intraoperative immunotherapy with the trifunctional antibody catumaxomab in patients with ovarian cancer: Results from a phase II study.
Authors: R. Chekerov, A. Reinthaller, D. Reimer, T. Reimer, L. Angleitner-Boubenizek, M. Halfen, H. Lindhofer, I. Braicu, G. Oskay-özcelik, J. Sehouli
Journal: Journal of Clinical Oncology (2010)

5039 Background: Despite recent improvements in cytoreductive surgery followed by chemotherapy in patients (pts) with advanced ovarian cancer the relapse and mortality rates are still too high. In previous studies with pts suffering from malignant ascites due to ovarian cancer the trifunctional antibody catumaxomab has demonstrated the ability to kill EpCAM-positive tumor cells in the peritoneal cavity and to control the malignant ascites in recurrent ovarian cancer. This study was conducted to investigate the tolerability and feasibility of catumaxomab administered directly into the peritoneal cavity during primary cytoreductive surgery and post-operatively prior to standard chemotherapy with paclitaxel and platinum. Methods: Ovarian cancer pts undergoing radical surgery received one intraoperative (10 μ g) followed by four subsequent intraperitoneal (i.p.) dosages (10, 20, 50 and 150 μ g) of catumaxomab over 3 hours on days 7, 10, 13, and 16, respectively. Analysis of the safety endpoints evaluable after subjects completed 1 month of follow-up are presented. Results: Of the 58 screened pts 41 were evaluable for the safety analysis. All 41 pts experienced at least one treatment-emergent adverse event, for a total of 871 events. Most common adverse events were pyrexia, nausea, abdominal pain, and vomiting due to cytokine release. The complications decreased continuously down to zero up to the fourth and fifth infusion. The observed post-operative complication rate was 51.2% including anastomosis insufficiencies (3 pts), infections (8 pts), and pleural effusions (10 pts). Conclusions: The safety data reflect the mode of action of catumaxomab. We can therefore conclude that the intra-operative treatment approach is feasible but its potential role with regard to postoperative complications especially for anastomosis insufficiencies needs to be further investigated. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Fresenius Biotech GmbH, TRION Pharma GmbH Fresenius Biotech, GlaxoSmithKline TRION Pharma GmbH Fresenius Biotech
The Generation of Potent Dendritic Cells Can Be Modulated by Interaction between Immature Dendritic Cells and Invariant NK Cells with the Presence of Stimulatory Cytokines and TLR Agonist.
Authors: Deok-Hwan Yang, Bo-Hwa Choi, Hyun-Kyu Kang, Sang-Ki Kim, Yeo-Kyeoung Kim, Hyeoung-Joon Kim, Je-Jung Lee
Journal: Blood (2007)